Susta-Jet
Testosterone propionate 30mg
Testosterone phenylpropionate 60 mg
Testosterone isocaproate 60 mg
Testosterone decanoate 100 mg
Strength
250 mg/ml
Dosage
250 mg per week
Packaging
10 ml
DESCRIPTION
Treatment of hypogonadal men with Sust-Jet results in a clinically significant rise of plasma concentrations of testosterone, dihydrotestosterone, estradiol and androstenedione, as well as decrease of SHBG (Sex hormone binding globulin). Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are restored to the normal range. In hypogonadal men, treatment with Susta-Jet results in an improvement of testosterone deficiency symptoms. Moreover, treatment increases bone mineral density and lean body mass, and decreases body fat mass. Treatment also improves sexual function, including libido and erectile function. Treatment decreases serum LDL-C, HDL-C and triglycerides and increases haemoglobin and haematocrit, which may lead to polycythaemia. No clinically relevant changes in liver enzymes and PSA have been reported.
Testosterone also produces systemic effects, such as increasing the retention of sodium, potassium and chloride leading to an increase in water retention. Treatment may result in an increase in prostate size, and worsening of lower urinary tract symptoms, but no adverse effects on prostate symptoms have been observed. In hypogonadal diabeteic patients, improvement of insulin sensitivity and/or reduction in blood glucose have been reported with the use of androgens. In boys with constitutional delay of growth and puberty, treatment with Susta-Jet accelerates growth and induces development of secondary sex characteristics. In female-to-male transsexuals, treatment with Susta-Jet induces masculinisation.